Cargando…
Electrochemical Carbamazepine Aptasensor for Therapeutic Drug Monitoring at the Point of Care
[Image: see text] Monitoring the anti-epileptic drug carbamazepine (CBZ) is crucial for proper dosing, optimizing a patient’s clinical outcome, and managing their medication regimen. Due to its narrow therapeutic window and concentration-related toxicity, CBZ is prescribed and monitored in a highly...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical Society
2022
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9631757/ https://www.ncbi.nlm.nih.gov/pubmed/36340178 http://dx.doi.org/10.1021/acsomega.2c04865 |
_version_ | 1784823885984694272 |
---|---|
author | Chung, Saeromi Singh, Naveen K. Gribkoff, Valentin K. Hall, Drew A. |
author_facet | Chung, Saeromi Singh, Naveen K. Gribkoff, Valentin K. Hall, Drew A. |
author_sort | Chung, Saeromi |
collection | PubMed |
description | [Image: see text] Monitoring the anti-epileptic drug carbamazepine (CBZ) is crucial for proper dosing, optimizing a patient’s clinical outcome, and managing their medication regimen. Due to its narrow therapeutic window and concentration-related toxicity, CBZ is prescribed and monitored in a highly personalized manner. We report an electrochemical conformation-changing aptasensor with two assay formats: a 30 min assay for routine monitoring and a 5 min assay for rapid emergency testing. To enable “sample-to-answer” testing, a de novo CBZ aptamer (K(d) < 12 nM) with conformational switching due to a G-quadruplex motif was labeled with methylene blue and immobilized on a gold electrode. The electrode fabrication and detection conditions were optimized using electrochemical techniques and visualized by atomic force microscopy (AFM). The aptasensor performance, including reproducibility, stability, and interference, was characterized using electrochemical impedance spectroscopy and voltammetry techniques. The aptasensor exhibited a wide dynamic range in buffer (10 nM to 100 μM) with limits of detection of 1.25 and 1.82 nM for the 5 and 30 min assays, respectively. The clinical applicability is demonstrated by detecting CBZ in finger prick blood samples (<50 μL). The proposed assays provide a promising method to enable point-of-care monitoring for timely personalized CBZ dosing. |
format | Online Article Text |
id | pubmed-9631757 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | American Chemical Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-96317572022-11-04 Electrochemical Carbamazepine Aptasensor for Therapeutic Drug Monitoring at the Point of Care Chung, Saeromi Singh, Naveen K. Gribkoff, Valentin K. Hall, Drew A. ACS Omega [Image: see text] Monitoring the anti-epileptic drug carbamazepine (CBZ) is crucial for proper dosing, optimizing a patient’s clinical outcome, and managing their medication regimen. Due to its narrow therapeutic window and concentration-related toxicity, CBZ is prescribed and monitored in a highly personalized manner. We report an electrochemical conformation-changing aptasensor with two assay formats: a 30 min assay for routine monitoring and a 5 min assay for rapid emergency testing. To enable “sample-to-answer” testing, a de novo CBZ aptamer (K(d) < 12 nM) with conformational switching due to a G-quadruplex motif was labeled with methylene blue and immobilized on a gold electrode. The electrode fabrication and detection conditions were optimized using electrochemical techniques and visualized by atomic force microscopy (AFM). The aptasensor performance, including reproducibility, stability, and interference, was characterized using electrochemical impedance spectroscopy and voltammetry techniques. The aptasensor exhibited a wide dynamic range in buffer (10 nM to 100 μM) with limits of detection of 1.25 and 1.82 nM for the 5 and 30 min assays, respectively. The clinical applicability is demonstrated by detecting CBZ in finger prick blood samples (<50 μL). The proposed assays provide a promising method to enable point-of-care monitoring for timely personalized CBZ dosing. American Chemical Society 2022-10-17 /pmc/articles/PMC9631757/ /pubmed/36340178 http://dx.doi.org/10.1021/acsomega.2c04865 Text en © 2022 The Authors. Published by American Chemical Society https://creativecommons.org/licenses/by-nc-nd/4.0/Permits non-commercial access and re-use, provided that author attribution and integrity are maintained; but does not permit creation of adaptations or other derivative works (https://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Chung, Saeromi Singh, Naveen K. Gribkoff, Valentin K. Hall, Drew A. Electrochemical Carbamazepine Aptasensor for Therapeutic Drug Monitoring at the Point of Care |
title | Electrochemical
Carbamazepine Aptasensor for Therapeutic
Drug Monitoring at the Point of Care |
title_full | Electrochemical
Carbamazepine Aptasensor for Therapeutic
Drug Monitoring at the Point of Care |
title_fullStr | Electrochemical
Carbamazepine Aptasensor for Therapeutic
Drug Monitoring at the Point of Care |
title_full_unstemmed | Electrochemical
Carbamazepine Aptasensor for Therapeutic
Drug Monitoring at the Point of Care |
title_short | Electrochemical
Carbamazepine Aptasensor for Therapeutic
Drug Monitoring at the Point of Care |
title_sort | electrochemical
carbamazepine aptasensor for therapeutic
drug monitoring at the point of care |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9631757/ https://www.ncbi.nlm.nih.gov/pubmed/36340178 http://dx.doi.org/10.1021/acsomega.2c04865 |
work_keys_str_mv | AT chungsaeromi electrochemicalcarbamazepineaptasensorfortherapeuticdrugmonitoringatthepointofcare AT singhnaveenk electrochemicalcarbamazepineaptasensorfortherapeuticdrugmonitoringatthepointofcare AT gribkoffvalentink electrochemicalcarbamazepineaptasensorfortherapeuticdrugmonitoringatthepointofcare AT halldrewa electrochemicalcarbamazepineaptasensorfortherapeuticdrugmonitoringatthepointofcare |